Nov. 15, 2018—Kevin Warren has been named senior director of Vanderbilt Environmental Health and Safety, effective Oct. 1. He fills the position vacated by Bob Wheaton, who retired in June.
Nov. 15, 2018—Research by Vanderbilt scientists suggests that it may be possible to prevent or even reverse pulmonary arterial hypertension, a rare, progressive disease characterized by narrowing of and high blood pressure in the small arteries of the lungs.
Nov. 15, 2018—New epilepsy monitoring systems at Vanderbilt University Medical Center are providing neurologists better data for assessing adult and pediatric patients.
Nov. 15, 2018—Lynne Maquat, PhD, recipient of the 2017 Vanderbilt Prize in Biomedical Science whose work has advanced our understanding of human gene expression, will deliver her Vanderbilt Prize lecture as part of the Flexner Discovery Lecture series on Nov. 29.
Nov. 15, 2018—David G. Harrison, MD, the Betty and Jack Bailey Professor of Cardiology and director of the Division of Clinical Pharmacology at Vanderbilt University School of Medicine, has been awarded the American Heart Association’s Basic Research Prize for 2018.
Nov. 15, 2018—Four Vanderbilt University researchers are among 200 recipients of this year’s Young Investigator Grants awarded by the Brain & Behavior Research Foundation to support “innovative ideas for groundbreaking neurobiological research.”
Nov. 15, 2018—This month marks the one-year anniversary of VUMC’s transition to eStar, and, as expected, there have been challenges and successes along the way.
Nov. 15, 2018—Megan Palmer, RN, a nurse in the Palliative Care Unit at Vanderbilt University Medical Center, wears many hats, but she never imagined writing a song about a perfect Stetson cowboy hat would hold such powerful meaning in her life.
Nov. 15, 2018—Sarah Rohde long had an interest in treating cancer, and her research during her undergraduate and medical school years at the University of Virginia underscored that. What she didn’t expect was to become a surgeon.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.